ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common ...

A new study, published in the New England Journal of Medicine, examines whether removing lymph nodes is always necessary in ...

BOSTON & MONTREAL, December 30, 2024--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage ...

Pembrolizumab is under clinical development by Merck and currently in Phase II for Anal Cancer. According to GlobalData, Phase II drugs for Anal Cancer have a 19% phase transition success rate (PTSR) ...

Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase I for Solid Tumor.

Investigators sought to determine the safety and accuracy of remote cutaneous confocal microscopy vs histopathological diagnosis of melanoma and keratinocyte carcinoma.

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

In Kashmir, lifestyle changes are helping cervical cancer cases rise, years after cultural factors limited incidence ...

In 2022, over 600,000 people across the world were diagnosed with bladder cancer, a 7.1% increase from 2020, putting their ...

Early results from a clinical trial appear to confirm that most women with the precancerous breast condition known as ductal ...

Each year, more than 56,500 women are diagnosed with ductal carcinoma in situ (DCIS), a non-invasive type of breast cancer commonly referred to as Stage 0 breast cancer. A woman with DCIS is ...

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma In this trial, patients with recurrent ...